Indeed, recent work demonstrated that targeting CDK7, P-TEFb, and CDK12/13 with potent small-molecule inhibitors could lead to vigorous anti-tumor effects in xenograft and pre-clinical models of cancer (20–24). Here, CDK7 is linked to cancer.